Published in final edited form as:

Eur J Med Chem. 2014 July 23; 82: 204–213. doi:10.1016/j.ejmech.2014.05.050.

Discovery of HDAC Inhibitors with Potent Activity Against Multiple Malaria Parasite Life Cycle Stages

Finn K. Hansen^a, Subathdrage D. M. Sumanadasa^b, Katharina Stenzel^a, Sandra Duffy^b, Stephan Meister^c, Linda Marek^a, Rebekka Schmetter^a, Krystina Kuna^a, Alexandra Hamacher^a, Benjamin Mordmüller^{d,e}, Matthias U. Kassack^a, Elizabeth A. Winzeler^c, Vicky M. Avery^b, Katherine T. Andrews^{*,b,1}, and Thomas Kurz^{*,a,1}

^aInstitut für Pharmazeutische und Medizinische Chemie, Heinrich Heine Universität Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany

^bEskitis Institute for Drug Discovery, Don Young Road, Nathan Campus, Griffith University, QLD 4111, Australia

^cDepartment of Pediatrics, University of California, San Diego, School of Medicine, 9500 Gilman Drive 0741, La Jolla, CA 92093

^dInstitut für Tropenmedizin, Eberhard Karls Universität Tübingen, Wilhelmstr. 27, 72074 Tübingen, Germany

^eMedical Research Laboratory, Albert Schweitzer Hospital, Lambaréné, Gabon

Abstract

In this work we investigated the antiplasmodial activity of a series of HDAC inhibitors containing an alkoxyamide connecting-unit linker region. HDAC inhibitor **1a** (LMK235), previously shown to be a novel and specific inhibitor of human HDAC4 and 5, was used as a starting point to rapidly construct a mini-library of HDAC inhibitors using a straightforward solid-phase supported synthesis. Several of these novel HDAC inhibitors were found to have potent *in vitro* activity against asexual stage *P. falciparum* malaria parasites. Representative compounds were shown to hyperacetylate *P. falciparum* histones and to inhibit deacetylase activity of recombinant PfHDAC1 and *P. falciparum* nuclear extracts. All compounds were also screened *in vitro* for activity against *P. berghei* exo-erythrocytic stages and selected compounds were further tested against late stage (IV and V) *P. falciparum* gametocytes. Of note, some compounds showed

*corresponding authors: Prof. Dr. Thomas Kurz, Institut für Pharmazeutische und Medizinische Chemie, Heinrich Heine Universität Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany. Tel.: (+49) 21181 14984. Fax: (+49) 21181 13847. Thomas.kurz@uni-duesseldorf.de. Assoc. Prof. Dr. Katherine T. Andrews, Eskitis Institute for Drug Discovery, Don Young Road, Nathan Campus, Griffith University, QLD 4111, Australia. Tel.: (+61) 73735 4420. Fax: (+61) 73735 6001. k.andrews@griffith.edu.au.

¹TK and KTA contributed equally to this work as senior authors.

Dedication

Dedicated to Prof. Dr. Alan R. Katritzky, in memoriam.

Supplementary Data

Supplementary data related to this article can be found online.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

nanomolar activity against all three life cycle stages tested (asexual, exo-erythrocytic and gametocyte stages) and several compounds displayed significantly increased parasite selectivity compared to the reference HDAC inhibitor suberoylanilide hydroxamic acid (SAHA). These data suggest that it may be possible to develop HDAC inhibitors that target multiple malaria parasite life cycle stages.

Keywords

Histone deacetylase inhibitor; malaria; liver stages; asexual blood stages; gametocyte stages

1. Introduction

Despite decades of research on its prevention and treatment, malaria remains a significant disease in tropical and subtropical regions of the world. As reported by the World Health Organization (WHO), 3.3 billion people were at risk of malaria in 2011, which is approximately half of the world's population [1]. In 2010 alone it is estimated that there were ~1.2 million malaria related deaths [2], the vast majority of which were due to infection with *Plasmodium falciparum* parasites. There is currently no licensed malaria vaccine and recent clinical trials in African children with the most advanced candidate, RTS,S/AS02D, were disappointing, with only ~30% protection being achieved over 18 months follow-up [3,4]. Hence, antimalarial drugs currently remain the most effective tool for malaria treatment and, together with vector control strategies, for malaria prophylaxis. Unfortunately, the rapid spread of drug-resistant *P. falciparum* parasites is compromising antimalarial drug efficacy in a clinical setting [5]. Alarming signs of emerging resistance to artemisinin derivatives [6,7] could threaten the now widely-used artemisinin combination therapies (ACTs) and highlight the urgent need to discover and develop new antimalarials with novel modes of action. Drugs that target different, or preferably multiple, parasite life cycle stages are also a high priority. Most current antimalarials are active against the asexual blood stages of the parasite, which are responsible for the clinical symptoms of malaria [1]. However, recent drug discovery efforts have moved towards eradication of malaria [8], and seek to additionally target exo-erythrocytic liver stages and gametocyte (transmission) stage parasites [9]. *Plasmodium* liver stages are clinically silent pre-erythrocytic life cycle stages that are promising targets for new drugs as inhibition of this stage leads to a true causal prophylaxis [10]. The transmission of malaria parasites to the female *Anopheles* mosquito vector occurs when sexual stage gametocytes are taken up in the blood of an infected individual during a blood meal. Following fertilization, meiosis and sporogony in the mosquito, progeny parasites can then be transmitted to another host when the female mosquito feeds again. A considerable number of drugs, which kill asexual parasites and alleviate symptoms, do not kill late stage gametocytes, allowing the infected individual to continue to spread the disease even after symptoms have disappeared [11]. Therefore, therapeutically blocking transmission is also a high priority for the malaria elimination agenda [11,12].

One promising strategy to identify new antimalarial agents is the “piggyback” approach, which focuses on drug targets that have been validated for other diseases. Using this

approach, we, and others, have previously investigated the antimalarial potential of compounds that target histone deacetylase (HDAC) enzymes [13,14]. While no HDAC inhibitor has yet been used clinically for malaria, this class of compound has been progressed to clinical use for cancer. Both the hydroxamate-based pan-HDAC inhibitor, vorinostat (suberoylanilide hydroxamic acid (SAHA)), and the class I selective prodrug, romidepsin (FK228), have been approved for treatment of cutaneous T-cell lymphoma (CTCL) [15–21]. The *P. falciparum* genome contains at least five putative HDACs [22] and the enzyme *P. falciparum* histone deacetylase 1 (*Pf*HDAC1) has been identified as a target of antimalarial HDAC inhibitors [23]. Treatment of *P. falciparum* parasites with HDAC inhibitors results in genome wide transcriptional alterations [24–26] and altered *Pf*HDAC1 expression has been found in *P. falciparum* parasite lines with reduced clinical susceptibility to artemisinin [27]. Together these findings underscore *Pf*HDACs' potential as novel parasite drug targets. The structures and properties of selected hydroxamate-based HDAC inhibitors with antimalarial activity are summarized in Table 1.

Despite some progress in recent years, there are still a number of challenges in the rational development of HDAC inhibitors as antimalarial drug leads. Next generation compounds should retain potent antiplasmodial activity and low host cell toxicity, but they also require improved pharmacokinetic properties relative to current generation compounds. In addition, while most work to date has focused on asexual stage parasites [13], we recently showed that two HDAC inhibitors (SAHA and SB939; see Table 1 for structures) have potent activity ($IC_{50} \sim 150\text{nM}$) against exo-erythrocytic stage *Plasmodium* parasites [29]. This raises the possibility that HDAC inhibitors could be developed as causal prophylactic and/or transmission blocking agents.

In this work we investigated the antimalarial activity of a new type of HDAC inhibitor, containing an alkoxyamide connecting-unit linker region [30], against different parasite life cycle stages. Previous work on the cytotoxicity and HDAC inhibitory activity of these alkoxyamide-based HDAC inhibitors against different human cisplatin sensitive and resistant cancer cell lines revealed potent cytotoxic properties and led to the discovery of **1a** (LMK235). Compound **1a** (LMK235) has a unique selectivity toward human HDAC4 and 5, which are inhibited with low nanomolar IC_{50} values [30]. To determine if this new type of HDAC inhibitor has antimalarial potential, we investigated the antimalarial activity of **1a** (LMK235) and a panel of analogues generated via solid-phase supported synthesis. All compounds were tested for *in vitro* activity against asexual stage *P. falciparum* parasites, exo-erythrocytic *Plasmodium* parasites cultured in HepG2 liver cells and for cytotoxicity against HepG2 liver cells. Selected compounds were then examined for gametocytocidal properties as well as inhibition of *Pf*HDAC1 enzyme activity and the ability to hyperacetylate histones in asexual stage *P. falciparum* parasites.

2. Results and discussion

2.1. Synthesis

The conventional synthesis of compounds **1a–h** was published previously [30]. In order to obtain a more rapid and convenient access to alkoxyamide-based HDAC inhibitors of type **1**, we developed the 5-step solid-phase synthesis illustrated in Scheme 1. The commercially

available Fmoc-hydroxylamine-2-chlorotrityl resin **2** was chosen as suitable solid support. First, the polymer-bound phthaloyl-protected linker **3** was prepared in two steps by deprotection of the Fmoc group and subsequent acylation of the free hydroxylamine moiety with 6-((1,3-dioxoisindolin-2-yl)oxy)hexanoic acid (4 equiv.) using DIC/Oxyma (4 equiv.) as coupling agents. Subsequently, the phthaloyl protection was cleaved with methylhydrazine to provide the resin-bound key intermediate **4**, which allowed the solid-phase synthesis of the alkoxyamide-based HDAC inhibitors **1i-u**. Our mini library of HDAC inhibitors was prepared using resin **4** and 13 different benzoic acid derivatives. First, the desired cap group (3 equiv.) was introduced by DIC/Oxyma-mediated (3 equiv.) amide coupling reaction to give the resinbound HDAC inhibitors **5i-u**. The DIC/Oxyma system in the absence of a base was chosen to prevent any possible *N*-overacylation of the NH-O function, which is a well-known side reaction in the synthesis of aminoxy-based compounds particularly observed under solid-phase reaction conditions [31–34]. Finally, HDAC inhibitors **1i-u** were conveniently released from the resin by treatment of **5i-u** with 5% trifluoroacetic acid (TFA) in dichloromethane. Purification by flash column chromatography provided the target compounds **1i-u** in 14–36% overall yields (over five steps).

2.2. In vitro activity against *P. falciparum* asexual blood stages

The antimalarial activity of alkoxyamide-based HDAC inhibitors **1a-u** was first tested against asexual-stage *P. falciparum* parasites using a tritiated hypoxanthine incorporation assay. Based on calculated physicochemical properties, all compounds were within the limits of Lipinski's rule of five [35] and were thus expected to be cell permeable (see Table 2 for calculated logP values). When tested for *in vitro* activity against the chloroquine-sensitive *P. falciparum* 3D7 line, 50% inhibitory concentration values (IC₅₀s) were in the range of 0.09–1.12 μM (Table 2). Compound **1i** was the most active compound in this series (R = 4-*t*-Bu-Ph, *Pf* 3D7 IC₅₀: 0.09 μM). Apparently, derivatives bearing alkyl groups in *m*- or *p*-position of the phenyl core exhibited more potent activity compared to the *o*-methyl derivative **1h** (IC₅₀: 1.12 μM). Interestingly, the dimethylphenyl-substituted compounds were more active than their respective mono-methyl counterparts. The potency increases with the bulkiness of the alkyl group in *p*-position (4-*t*-Bu-Ph (**1i**) > 4-*i*-Pr-Ph (**1c**) > 4-CH₃-Ph (**1e**); Table 2). A similar pattern is observed for the alkoxy-substituted compounds, where the 4-isopropoxyphenyl derivative **1j** (IC₅₀: 0.15 μM) showed the highest activity against *P. falciparum*. It is worth noting that introducing a (1,1'-biphenyl)-4-yl cap group, as in **1k**, does not significantly alter the activity (IC₅₀: 0.16 μM), which indicates that bulky substituents are well tolerated.

2.3. Cytotoxicity and selectivity indices

To assess the selectivity of alkoxyamide-based HDAC inhibitors for the parasite versus mammalian cells, cytotoxicity was evaluated against HepG2 liver cells. The results and selectivity indices (SIs) are outlined in Table 2. All compounds with a methyl group in *m*-position of the phenyl ring showed only moderate parasite selectivity (SI: 13–27). However, several other compounds revealed significantly increased selectivity for the parasite compared to the reference HDAC inhibitor SAHA (SI: 11, Table 2). As already observed for the activity against asexual blood stages, the parasite selectivity increases with the bulkiness

of the alkyl group in *p*-position (4-*t*-Bu-Ph (**1i**, SI: 139) > 4-*i*-Pr-Ph (**1c**, SI: 73) > 4-CH₃-Ph (**1e**, SI: 55); Table 2). In addition, the bulky biphenyl-based compound **1k** (SI: 64) showed increased selectivity for the parasite compared to SAHA (SI: 11). The selectivity indices of the alkoxy-substituted compounds are particularly interesting. The 2- and 3-propoxy-substituted compounds (**1p** and **1q**, SI: 34 and 29, respectively) are significantly less parasite selective than the 4-propoxy analogue **1m** (SI: 80). The truncated 4-ethoxy derivative **1o** (SI: 33) displayed a decreased selectivity index compared to **1m**. Remarkably, all elongated alkoxy compounds showed no cytotoxicity at the highest concentration tested (50 μM) and the butoxy- (**1l**), pentoxy- (**1n**) and hexoxy-substituted (**1s**) HDAC inhibitors revealed promising selectivity indices with >294, >238 and >143, respectively. These data indicate that the introduction of bulky- and alkoxy-substituted cap groups on HDAC inhibitors of type **1** might be a useful tool for the development of antimalarial lead compounds with potent and selective action against *P. falciparum*.

2.4. Mode of action of alkoxyamide-based HDAC inhibitors in asexual-stage *P. falciparum* parasites

The mode of action of eight representative alkoxyamide-based HDAC inhibitors in asexual-stage parasites was assessed by examining *in situ* hyperacetylation of *P. falciparum* histones and *in vitro* activity against *P. falciparum* nuclear lysates and recombinant PfHDAC1. Like the control compound TSA, **1a–1d** and **1i–1l** caused hyperacetylation of *P. falciparum* histone H4 (Figure 1). Histone H3 was also hyperacetylated by all eight compounds, although apparently to a lesser extent by **1b** (Figure 1). The reason for this is not yet known, however the effect was not due to unequal loading, as the same membrane was also probed with control antisera (anti-IC3/94) to confirm equivalent protein levels were present.

Compounds **1a–d** and **1i–1l** were also tested for their ability to inhibit deacetylase activity in *P. falciparum* nuclear lysates and the activity of recombinant PfHDAC1. All compounds displayed >50% inhibition of PfHDAC1 activity at 1 μM and all but **1j** > ~50% inhibition of *P. falciparum* nuclear extract at 1 μM (Table 3). The reason for a lack of deacetylase inhibition by **1j** is not yet known, however compound stability can be ruled out, as this compound was still active in the other mode of action assays (Figure 1; Table 3). Once additional recombinant PfHDAC proteins become available it will be important to profile this compound and other HDAC inhibitors against different malaria HDAC enzymes.

2.5. In vitro activity against tissue schizontocidal stages of *P. berghei*

We showed previously that two commercially available HDAC inhibitors, SAHA and SB939, can potently inhibit exo-erythrocytic stage *P. berghei* parasite development *ex vivo* in HepG2 liver cells (IC₅₀ ~0.15 μM) [29]. This prompted us to assess the activity of our novel HDAC inhibitors against this life cycle stage. Five of 21 compounds tested (**1a**, **1b**, **1d**, **1p** and **1q**) displayed potent activity against *P. berghei* exo-erythrocytic stages with IC₅₀ values ranging from 0.16–0.66 μM, 13 had moderate activity with IC₅₀s between 1.13 – 2.54 μM, while three (**1m**, **1n** and **1s**) showed no activity with IC₅₀ values > 5 μM (Table 4). Remarkably, the most active compounds all bear a methyl group in the 3-position of the phenyl ring (**1a**, **1b**, and **1d**) or a propoxy group in 2- or 3-position (**1p** and **1q**).

A comparison of the IC₅₀ values for *P. berghei* exo-erythrocytic stages with those obtained for HepG2 liver cells indicate a moderate parasite-specific selectivity for compounds with sub- μ M IC₅₀s (SI ~ 7–17; Table 4). These selectivity indices are comparable with the selectivity of the reference compound SAHA (SI = 11, Table 4). Some of the alkoxy-substituted derivatives in this study were not cytotoxic at the highest concentration tested (50 μ M) indicating that it should be possible to develop parasite-specific HDAC inhibitors that selectively target exo-erythrocytic stage parasites. In particular compound **1l** (SI: > 23) will be the subject of future work to determine if this compound has potential as chemical starting point for exo-erythrocytic stage drug development.

2.6. In vitro activity against late stage gametocytes

There is an increasing focus on the elimination, rather than just prevention and treatment, of malaria and to achieve this it will be important to identify approaches to block the transmission of sexual (gametocyte) stage *Plasmodium* parasites to the mosquito vector. When we examined the activity of a sub-set of our alkoxyamide-based HDAC inhibitors against late-stage gametocytes (see Table 5), we found that five of nine compounds tested (**1a**, **1b**, **1d**, **1k** and **1t**) had IC₅₀ values < 1 μ M, two had less potent activity with IC₅₀ values between 2.0–5.3 μ M (**1g** and **1r**) while two (**1i** and **1u**) were not active (IC₅₀ > 120 μ M). As already observed for *P. berghei* exo-erythrocytic stages, a 3-methylphenyl substitution emerges as beneficial, as indicated by the potent activities of compounds **1a**, **1b**, and **1d** with IC₅₀s between 0.25–0.43 μ M. Notably, compound **1b**, bearing a methyl group in *m*- and *p*-position, was the most active compound of this series (IC₅₀ 0.25 μ M). Interestingly, compound **1k** displayed good activity against late-stage gametocytes (IC₅₀ 0.50 μ M). Hence, biphenyl-based HDAC inhibitors appear to be interesting scaffolds for the development of antimalarials with activity against sexual (gametocyte) stages.

A comparison of the IC₅₀ values of the four most potent compounds with those obtained for HepG2 cells (Table 2) indicates that **1a** is cytotoxic (SI = 4), while **1b** has around 13 fold, **1d** 11 fold and **1k** 20 fold more activity against late stage gametocytes versus mammalian cells. It is interesting to note that **1k** showed only moderate activity against exo-erythrocytic stages (*Pb* EEF IC₅₀: 1.83 μ M, Table 4). As we do not yet know which *Pf*HDACs are expressed in different life cycle stages, or their relative abundance, such differences in activity could be due to differences in HDAC isoform expression. Alternatively, differences could also be due to the use of different species of parasites in the respective assays (*P. berghei* versus *P. falciparum*). It is also possible that the differences we see are due to interference with the regulation of HDAC-associated stage-specific proteins or pathways, or even to action against alternative molecular targets.

3. Conclusions

Starting from **1a** (LMK235), a specific inhibitor of human HDAC4 and 5, we have now extended our studies to examine the activity of **1a** and novel structural analogues against *Plasmodium* malaria parasites. For this purpose, we developed a straightforward solid-phase synthesis allowing the rapid construction of mini libraries of HDAC inhibitors with an alkoxyamide connecting-unit linker region. Biological evaluation of a panel of 21

alkoxyamide-based HDAC inhibitors against the chloroquine-sensitive 3D7 line of *P. falciparum* revealed IC₅₀ values in the range of 0.09–1.12 μ M. Modification of the cap group showed that the nature of the substitution on the phenyl ring is crucial for the parasite selectivity. All compounds were tested *in vitro* for their activity against tissue schizontocidal stages of *P. berghei* (exo-erythrocytic forms) and selected compounds were further tested against sexual stage *P. falciparum* parasites (stage IV/V gametocytes). Notably, compounds **1a** (LMK235), **1b** and **1d** showed nanomolar activity against all three life cycle stages, while other compounds revealed increased parasite selectivity in combination with at least dual-stage activity. Thus, this series of compounds represents a valuable starting point for the development of novel antimalarial drug leads with potent antiplasmodial activity against multiple malaria parasite life cycle stages, low host cell toxicity, and causal prophylactic and/or transmission blocking properties.

4. Experimental Section

4.1. Synthesis

All solvents and chemicals were used as purchased without further purification. Column chromatography was performed with Macherey-Nagel silica gel 60 M (0.04 – 0.063 mm). TLC analysis was performed on Merck precoated silica gel plates (with fluorescence indicator UV₂₅₄). Spots were visualized by irradiation with ultraviolet light (254 nm). Melting points (mp) were taken in open capillaries on a Mettler FP 5 melting-point apparatus and are uncorrected. Proton (¹H) and carbon (¹³C) NMR spectra were recorded on a Bruker Avance 500 (500.13 MHz for ¹H; 125.76 MHz for ¹³C) using DMSO-*d*₆ as solvent. Chemical shifts are given in parts per million (ppm), (δ relative to residual solvent peak for ¹H and ¹³C or to tetramethylsilane). Elemental analysis was performed on a Perkin Elmer PE 2400 CHN elemental analyzer. IR spectra were recorded on a Varian 800 FT-IR Scimitar series. HRMS analysis was performed on a UHR-TOF maXis 4G, Bruker Daltonics, Bremen. HPLC purity determination was carried out using a Phenomenex Luna C-18(2) 1.8 μ m particle (250 mm $\times$ 4.6 mm) column, supported by Phenomenex Security Guard Cartridge Kit C18 (4.0 mm $\times$ 3.0 mm). The purity of all final compounds was 95% or higher. Fmoc-hydroxylamine-2-chlorotriyl resin was purchased from Iris Biotech, Germany. All solid phase reactions were carried out in a Heidolph Synthesis 1 parallel synthesizer. 3-Propoxybenzoic acid [37] and 6-((1,3-dioxoisindolin-2-yl)oxy)hexanoic acid [30] were prepared according to literature.

4.2. General Procedures for Solid-Phase Synthesis

4.2.1 General procedure for the coupling of 6-((1, 3-dioxoisindolin-2-yl) oxy) hexanoic acid to the resin—Fmoc-hydroxylamine-2-chlorotriyl resin (500 mg, 0.4 mmol, Iris Biotech) was treated with 20% piperidine in DMF (1 $\times$ 10 mL, 1h) and washed with CH₂Cl₂ (3 $\times$ 10 mL). A solution of 6-((1, 3-dioxoisindolin-2-yl) oxy) hexanoic acid (443 mg, 1.6 mmol), Oxyma (227 mg, 1.6 mmol) and DIC (202 mg, 1.6 mmol) in CH₂Cl₂ (10 mL) was added and the resin was shaken for 24h at room temperature. Afterward, the resin was drained and washed with CH₂Cl₂ (3 $\times$ 5 mL), MeOH (3 $\times$ 5 mL), CH₂Cl₂ (3 $\times$ 5 mL).

4.2.2. General procedure for the removal of the phthaloyl-protection group—

The resin was suspended in EtOH:THF (1:1, 10 mL) and methylhydrazine (1.5 mL, 28.7 mmol) was added. Subsequently, the resin was shaken at room temperature (3h). The resin was drained and washed with MeOH (3 × 5 mL), THF (3 × 5 mL), CH₂Cl₂ (3 × 5 mL).

4.2.3. General procedure for the coupling of benzoic acid derivatives—

A solution of the respective carboxylic acid (1.2 mmol), Oxyma (171 mg, 1.2 mmol) and DIC (151 mg, 1.2 mmol) in CH₂Cl₂ (10 mL) was added to the resin and shaken for 24h. The resin was washed with CH₂Cl₂ (3 × 5 mL), MeOH (3 × 5 mL), CH₂Cl₂ (3 × 5 mL).

4.2.4. General procedure for the cleavage of resin-bound HDAC inhibitors—

The resin was treated with 5% TFA in CH₂Cl₂ (1 × 10 mL) at room temperature (1h). The resin was drained and washed with CH₂Cl₂ (3 × 5 mL). The filtrates were combined and evaporated to dryness under reduced pressure. The crude products were purified by column chromatography using hexane/ethyl acetate (gradient) as eluent to afford the desired HDAC inhibitors.

4.3. Experimental data**4.3.1. 4-(tert-Butyl)-N-((6-(hydroxyamino)-6-oxohexyl)oxy)benzamide (1i)—**

White solid; yield 22%; mp 46 °C. ¹H NMR (500.13 MHz, DMSO-*d*₆): δ = 11.54 (s, 1H), 10.36 (s, 1H), 8.68 (s, 1H), 7.68 (d, *J* = 8.4 Hz, 2H), 7.48 (d, *J* = 8.4 Hz, 2H), 3.85 (t, *J* = 6.4 Hz, 2H), 1.96 (t, *J* = 7.3 Hz, 2H), 1.64 – 1.48 (m, 4H), 1.41 – 1.22 (m, 11H) ppm. ¹³C NMR (125.76 MHz, DMSO-*d*₆): δ = 168.89, 164.01, 154.22, 129.54, 126.78, 125.08, 74.96, 34.52, 32.08, 30.79, 27.34, 24.98, 24.81 ppm. IR (KBr): $\tilde{\nu}$ = 3200 (NH), 2954, 2873 (CH₂), 1642 (C=O) cm⁻¹. HRMS (ESI) [M+H]⁺: 323.19656, Calcd. for C₁₇H₂₇N₂O₄: 323.19653. HPLC analysis: retention time = 14.18 min; peak area: 97.86%. Eluent A: 5 mM NH₄OAc solution; eluent B: CH₃CN, gradient (95:5 → 5:95) over 20 min at a flow rate of 1.0 mL min⁻¹.

4.3.2. N-((6-(Hydroxyamino)-6-oxohexyl)oxy)-4-isopropoxybenzamide (1j)—

White solid; yield 23%; mp 125 °C. ¹H NMR (500.13 MHz, DMSO-*d*₆): δ = 11.45 (s, 1H), 10.36 (s, 1H), 8.68 (s, 1H), 7.69 (d, *J* = 8.7 Hz, 2H), 6.96 (d, *J* = 8.7 Hz, 2H), 4.76 – 4.64 (m, 1H), 3.84 (t, *J* = 6.4 Hz, 2H), 1.96 (t, *J* = 7.3 Hz, 2H), 1.65 – 1.48 (m, 4H), 1.44 – 1.30 (m, 2H), 1.27 (d, *J* = 6.0 Hz, 6H) ppm. ¹³C NMR (125.76 MHz, DMSO-*d*₆): δ = 168.92, 163.81, 159.96, 128.81, 124.00, 114.87, 74.96, 69.25, 32.10, 27.36, 25.00, 24.82, 21.59 ppm. IR (KBr): $\tilde{\nu}$ = 3358, 3181 (NH), 2938, 2868 (CH₂), 1666 (C=O) cm⁻¹. Anal. Calcd. for C₁₆H₂₄N₂O₅: C 59.24, H 7.46, N 8.64. Found: C 59.30, H 7.74, N 8.36.

4.3.3. N-((6-(Hydroxyamino)-6-oxohexyl)oxy)-[1,1'-biphenyl]-4-carboxamide (1k)—White solid; yield 27%; mp 155 °C. ¹H NMR (500.13 MHz, DMSO-*d*₆): δ = 11.69 (s, 1H), 10.37 (s, 1H), 8.69 (s, 1H), 7.89 – 7.82 (m, 2H), 7.80 – 7.75 (m, 2H), 7.75 – 7.69 (m, 2H), 7.53 – 7.47 (m, 2H), 7.44 – 7.38 (m, 1H), 3.89 (t, *J* = 6.4 Hz, 2H), 1.98 (t, *J* = 7.3 Hz, 2H), 1.66 – 1.50 (m, 4H), 1.43 – 1.31 (m, 2H) ppm. ¹³C NMR (125.76 MHz, DMSO-*d*₆): δ = 168.91, 163.73, 142.95, 138.96, 131.08, 128.93, 128.01, 127.62, 126.75, 126.53, 75.04, 32.10, 27.36, 24.99, 24.82 ppm. IR (KBr): $\tilde{\nu}$ = 3222 (NH), 2942, 2862 (CH₂), 1648 (C=O)

cm⁻¹. Anal. Calcd. for C₁₉H₂₂N₂O₄: C 66.65, H 6.48, N 8.18. Found: C 66.50, H 6.33, N 8.09.

4.3.4. 4-Butoxy-N-((6-(hydroxyamino)-6-oxohexyl)oxy)benzamide (1l)—White solid; yield 18%; mp 125 °C. ¹H NMR (500.13 MHz, DMSO-*d*₆): δ = 11.46 (s, 1H), 10.36 (s, 1H), 8.67 (s, 1H), 7.70 (d, *J* = 8.7 Hz, 2H), 6.98 (d, *J* = 8.8 Hz, 2H), 4.01 (t, *J* = 6.5 Hz, 2H), 3.84 (t, *J* = 6.4 Hz, 2H), 1.96 (t, *J* = 7.3 Hz, 2H), 1.76 – 1.64 (m, 2H), 1.63 – 1.48 (m, 4H), 1.48 – 1.28 (m, 4H), 0.93 (t, *J* = 7.4 Hz, 3H) ppm. ¹³C NMR (125.76 MHz, DMSO-*d*₆): δ = 168.92, 163.80, 161.13, 128.76, 124.22, 113.98, 74.97, 67.27, 32.10, 30.51, 27.37, 25.00, 24.83, 18.59, 13.58 ppm. IR (KBr): ν̄=3220, 3120 (NH), 2935, 2871 (CH₂), 1619 (C=O) cm⁻¹. Anal. Calcd. for C₁₇H₂₆N₂O₅: C 60.34, H 7.74, N 8.28. Found: C 60.01, H 7.78, N 8.48.

4.3.5. N-((6-(Hydroxyamino)-6-oxohexyl)oxy)-4-propoxybenzamide (1m)—White solid; yield 32%; mp 112 °C. ¹H NMR (500.13 MHz, DMSO-*d*₆): δ = 11.48 (s, 1H), 10.37 (s, 1H), 8.68 (s, 1H), 7.71 (d, *J* = 8.7 Hz, 2H), 6.98 (d, *J* = 8.7 Hz, 2H), 3.97 (t, *J* = 6.5 Hz, 2H), 3.84 (t, *J* = 6.5 Hz, 2H), 1.96 (t, *J* = 7.4 Hz, 2H), 1.78 – 1.68 (m, 2H), 1.63 – 1.48 (m, 4H), 1.40 – 1.30 (m, 2H), 0.97 (t, *J* = 7.4 Hz, 3H) ppm. ¹³C NMR (125.76 MHz, DMSO-*d*₆): δ = 168.89, 163.77, 161.09, 128.74, 124.19, 113.96, 74.95, 69.01, 32.09, 27.36, 24.99, 24.82, 21.82, 10.23 ppm. IR (KBr): ν̄=3214 (NH), 2939, 2869 (CH₂), 1669 (C=O) cm⁻¹. Anal. Calcd. for C₁₆H₂₄N₂O₅: C 59.24, H 7.46, N 8.64. Found: C 59.45, H 7.56, N 8.42.

4.3.6. N-((6-(Hydroxyamino)-6-oxohexyl)oxy)-4-(pentyloxy)benzamide (1n)—White solid; yield 28%; mp 110 °C. ¹H NMR (500.13 MHz, DMSO-*d*₆): δ = 11.46 (s, 1H), 10.35 (s, 1H), 8.67 (s, 1H), 7.70 (d, *J* = 8.8 Hz, 2H), 6.98 (d, *J* = 8.8 Hz, 2H), 4.01 (t, *J* = 6.5 Hz, 2H), 3.84 (t, *J* = 6.5 Hz, 2H), 1.96 (t, *J* = 7.3 Hz, 2H), 1.77 – 1.67 (m, 2H), 1.63 – 1.48 (m, 4H), 1.46 – 1.27 (m, 6H), 0.89 (t, *J* = 7.1 Hz, 3H) ppm. ¹³C NMR (125.76 MHz, DMSO-*d*₆): δ = 168.90, 163.76, 161.10, 128.74, 124.21, 113.97, 74.94, 67.54, 32.10, 28.15, 27.55, 27.37, 25.00, 24.82, 21.77, 13.81 ppm. IR (KBr): ν̄=3211 (NH), 2940 (CH₂), 1672, 1616 (C=O) cm⁻¹. Anal. Calcd. for C₁₈H₂₈N₂O₅: C 61.34, H 8.01, N 7.95. Found: C 61.14, H 8.16, N 7.72.

4.3.7. 4-Ethoxy-N-((6-(hydroxyamino)-6-oxohexyl)oxy)benzamide (1o)—White solid; yield 25%; mp 125 °C. ¹H NMR (500.13 MHz, DMSO-*d*₆): δ = 11.46 (s, 1H), 10.35 (s, 1H), 8.67 (s, 1H), 7.71 (d, *J* = 8.8 Hz, 2H), 6.97 (d, *J* = 8.8 Hz, 2H), 4.07 (q, *J* = 7.0 Hz, 2H), 3.84 (t, *J* = 6.4 Hz, 2H), 1.96 (t, *J* = 7.3 Hz, 2H), 1.62 – 1.48 (m, 4H), 1.41 – 1.29 (m, 5H) ppm. ¹³C NMR (125.76 MHz, DMSO-*d*₆): δ = 168.92, 163.79, 160.95, 128.76, 124.23, 113.94, 74.97, 63.20, 32.10, 27.36, 25.00, 24.82, 14.42 ppm. IR (KBr): ν̄=3170 (NH), 2850 (CH₂), 1619 (C=O) cm⁻¹. Anal. Calcd. for C₁₅H₂₂N₂O₅: C 58.05, H 7.15, N 9.03. Found: C 57.81, H 7.25, N 8.97.

4.3.8. N-((6-(Hydroxyamino)-6-oxohexyl)oxy)-2-propoxybenzamide (1p)—White solid; yield 20%; mp 102 °C. ¹H NMR (500.13 MHz, DMSO-*d*₆): δ = 10.95 (s, 1H), 10.35 (s, 1H), 8.67 (s, 1H), 7.51 – 7.35 (m, 2H), 7.08 (d, *J* = 8.3 Hz, 1H), 6.99 (t, *J* = 7.4 Hz, 1H), 3.99 (t, *J* = 6.4 Hz, 2H), 3.85 (t, *J* = 6.5 Hz, 2H), 1.96 (t, *J* = 7.3 Hz, 2H), 1.80 – 1.68 (m,

2H), 1.66 – 1.47 (m, 4H), 1.42 – 1.27 (m, 2H), 0.98 (t, $J = 7.4$ Hz, 3H) ppm. ^{13}C NMR (125.76 MHz, DMSO- d_6): $\delta = 168.92, 163.20, 155.83, 131.65, 129.39, 122.91, 120.16, 112.59, 74.93, 69.54, 32.10, 27.24, 24.94, 24.84, 21.82, 10.32$ ppm. IR (KBr): $\tilde{\nu} = 3349, 3230$ (NH), $2936(\text{CH}_2), 1651(\text{C}=\text{O})\text{ cm}^{-1}$. HRMS (ESI) $[\text{M}+\text{H}]^+$: 325.17567, Calcd. for $\text{C}_{16}\text{H}_{25}\text{N}_2\text{O}_5$: 325.17580. HPLC analysis: retention time = 9.46 min; peak area: 97.52%. Eluent A: water; eluent B: methanol, gradient (50:50 $\rightarrow$ 0:100) over 20 min at a flow rate of 1.0 mL min^{-1} .

4.3.9. N-((6-(Hydroxyamino)-6-oxohexyl)oxy)-3-propoxybenzamide (1q)—White solid; yield 14%; mp $101\text{ }^\circ\text{C}$. ^1H NMR (500.13 MHz, DMSO- d_6): $\delta = 11.61$ (s, 1H), 10.36 (s, 1H), 8.68 (s, 1H), 7.44 – 7.22 (m, 3H), 7.09 (d, $J = 6.9$ Hz, 1H), 3.96 (t, $J = 6.5$ Hz, 2H), 3.86 (t, $J = 6.2$ Hz, 2H), 1.97 (t, $J = 7.3$ Hz, 2H), 1.79 – 1.68 (m, 2H), 1.64 – 1.49 (m, 4H), 1.42 – 1.30 (m, 2H), 0.99 (t, $J = 7.4$ Hz, 3H) ppm. ^{13}C NMR (125.76 MHz, DMSO- d_6): $\delta = 168.93, 163.74, 158.48, 133.63, 129.51, 119.06, 117.69, 112.60, 75.00, 69.00, 32.10, 27.35, 24.99, 24.82, 21.90, 10.29$ ppm. IR (KBr): $\tilde{\nu} = 3210$ (NH), 2938, 2874 (CH_2), 1670, 1624 ($\text{C}=\text{O})\text{ cm}^{-1}$. Anal. Calcd. for $\text{C}_{16}\text{H}_{24}\text{N}_2\text{O}_5$: C 59.24, H 7.46, N 8.64. Found: C 59.29, H 7.48, N 8.42.

4.3.10. 4-Butyl-N-((6-(hydroxyamino)-6-oxohexyl)oxy)benzamide (1r)—White solid; yield 20%; mp $119\text{ }^\circ\text{C}$. ^1H NMR (500.13 MHz, DMSO- d_6): $\delta = 11.54$ (s, 1H), 10.36 (s, 1H), 8.68 (s, 1H), 7.66 (d, $J = 8.1$ Hz, 2H), 7.27 (d, $J = 7.9$ Hz, 2H), 3.85 (t, $J = 6.5$ Hz, 2H), 2.61 (t, $J = 7.7$ Hz, 2H), 1.96 (t, $J = 7.4$ Hz, 2H), 1.64 – 1.47 (m, 6H), 1.43 – 1.23 (m, 4H), 0.89 (t, $J = 7.4$ Hz, 3H) ppm. ^{13}C NMR (125.76 MHz, DMSO- d_6): $\delta = 168.90, 164.04, 146.11, 129.75, 128.19, 126.96, 74.97, 34.52, 32.75, 32.09, 27.35, 24.99, 24.82, 21.58, 13.64$ ppm. IR (KBr): $\tilde{\nu} = 3205$ (NH), 2943, 2865 (CH_2), 1650 ($\text{C}=\text{O})\text{ cm}^{-1}$. Anal. Calcd. for $\text{C}_{17}\text{H}_{26}\text{N}_2\text{O}_4$: C 63.33, H 8.13, N 8.69. Found: C 63.15, H 8.37, N 8.86.

4.3.11. 4-(Hexyloxy)-N-((6-(hydroxyamino)-6-oxohexyl)oxy)benzamide (1s)—White solid; yield 36%; mp $105\text{ }^\circ\text{C}$. ^1H NMR (500.13 MHz, DMSO- d_6): $\delta = 11.46$ (s, 1H), 10.36 (s, 1H), 8.67 (s, 1H), 7.70 (d, $J = 8.7$ Hz, 2H), 6.98 (d, $J = 8.8$ Hz, 2H), 4.01 (t, $J = 6.5$ Hz, 2H), 3.84 (t, $J = 6.4$ Hz, 2H), 1.96 (t, $J = 7.3$ Hz, 2H), 1.76 – 1.65 (m, 2H), 1.63 – 1.47 (m, 4H), 1.46 – 1.23 (m, 8H), 0.88 (t, $J = 6.9$ Hz, 3H) ppm. ^{13}C NMR (125.76 MHz, DMSO- d_6): $\delta = 168.92, 163.80, 161.11, 128.75, 124.20, 113.98, 74.96, 67.56, 32.09, 30.86, 28.41, 27.54, 27.35, 25.02, 24.81, 21.95, 13.80$ ppm. IR (KBr): $\tilde{\nu} = 3237$ (NH), 2930 (CH_2), 1666, 1619 ($\text{C}=\text{O})\text{ cm}^{-1}$. Anal. Calcd. for $\text{C}_{19}\text{H}_{30}\text{N}_2\text{O}_5$: C 62.27, H 8.25, N 7.64. Found: C 62.38, H 8.40, N 7.35.

4.3.12. N-((6-(Hydroxyamino)-6-oxohexyl)oxy)furan-2-carboxamide (1t)—White solid; yield 32%; mp $113\text{ }^\circ\text{C}$. ^1H NMR (500.13 MHz, DMSO- d_6): $\delta = 11.61$ (s, 1H), 10.35 (s, 1H), 8.67 (s, 1H), 7.85 (s, 1H), 7.09 (d, $J = 3.1$ Hz, 1H), 6.63 (dd, $J = 3.1, 1.60$ Hz, 1H), 3.83 (t, $J = 6.4$ Hz, 2H), 1.95 (t, $J = 7.3$ Hz, 2H), 1.65 – 1.45 (m, 4H), 1.39 – 1.27 (m, 2H) ppm. ^{13}C NMR (125.76 MHz, DMSO- d_6): $\delta = 168.95, 155.91, 145.60, 145.30, 113.89, 111.61, 75.36, 32.08, 27.29, 24.93, 24.80$ ppm. IR (KBr): $\tilde{\nu} = 3250, 3137$ (NH), 2936, 2867 (CH_2), 1666 ($\text{C}=\text{O})\text{ cm}^{-1}$. Anal. Calcd. for $\text{C}_{11}\text{H}_{16}\text{N}_2\text{O}_5$: C 51.56, H 6.29, N 10.93. Found: C 51.56, H 6.46, N 10.72.

4.3.13. 2-Fluoro-N-((6-(hydroxyamino)-6-oxohexyl)oxy)benzamide (1u)—Orange solid; yield 26%; mp 122 °C. ¹H NMR (500.13 MHz, DMSO-*d*₆): δ = 11.46 (s, 1H), 10.36 (s, 1H), 8.68 (s, 1H), 7.60 – 7.50 (m, 2H), 7.34 – 7.25 (m, 2H), 3.87 (t, *J* = 6.5 Hz, 2H), 1.96 (t, *J* = 7.4 Hz, 2H), 1.66 – 1.47 (m, 4H), 1.42 – 1.30 (m, 2H) ppm. ¹³C NMR (125.76 MHz, DMSO-*d*₆): δ = 168.92, 160.99, 158.89 (d, ¹*J*_{C,F} = 249.2 Hz), 132.58 (d, ³*J*_{C,F} = 8.4 Hz), 128.86 (d, ⁴*J*_{C,F} = 3.1 Hz), 124.47 (d, ³*J*_{C,F} = 3.6 Hz), 121.85 (d, ²*J*_{C,F} = 15.6 Hz), 116.00 (d, ²*J*_{C,F} = 21.9 Hz), 75.08, 32.09, 27.23, 24.91, 24.81 ppm. IR (KBr): ν̄ = 3297 (NH), 2949, 2878 (CH₂), 1673, 1635 (C=O) cm⁻¹. Anal. Calcd. for C₁₃H₁₇FN₂O₄: C 54.92, H 6.03, N 9.85. Found: C 55.05, H 6.31, N 9.65.

4.4. Asexual stage in vitro antimalarial assays

Activity against asexual stage *P. falciparum* line 3D7 was determined using [³H]-hypoxanthine incorporation, essentially as previously described [29,38]. Serial dilutions of compounds were prepared in parasite culture media (RPMI 1640 supplemented with 10% heat inactivated human serum), followed by addition of synchronous ring-stage parasites 0.25% parasitaemia and 2.5% haematocrit. Following incubation for 48h at 37°C under standard parasite culture conditions, [³H]-hypoxanthine (0.5μCi/well) was added to each well, and the cultures incubated for a further 24h. [³H]-hypoxanthine incorporation was measured by harvesting onto 1450 MicroBeta filter mats (Wallac) and counting using a 1450 MicroBeta liquid scintillation counter. Percentage inhibition of growth compared to matched DMSO controls (0.5%) was determined. Three independent experiments were carried out, each in triplicate wells. Chloroquine was included in each assay as a positive control. IC₅₀ values were determined using log-linear interpolation of inhibition curves [39] and are presented as mean (± SD) of the three independent assays.

4.6. Histone hyperacetylation assays

The effect of compounds on histone hyperacetylation was determined essentially as previously described [29]. Briefly, synchronous trophozoite-stage *P. falciparum* 3D7 parasites were incubated for 3 h under standard *in vitro* culture conditions with 500 nM of test compounds or vehicle control (0.05% DMSO). The antimalarial drug chloroquine (500 nM) was included as a negative control and TSA was included as a HDAC inhibitor positive control. Vehicle control samples were taken at the start (t=0) and end (t=3 h) of the treatment. Protein lysates were prepared by lysing cells with saponin (Sigma, USA) and extensive washing in phosphate buffered saline to remove haemoglobin. Parasite pellets were resuspended in SDS-PAGE loading dye, heat denatured at 96°C then separated via 15% SDS-PAGE. Western blot was carried out using Odyssey reagents (LI-COR Biosciences) according to the manufacturers' instructions. The following primary antisera were used: anti-(tetra) acetyl H4 (Millipore) which recognizes lysines 5, 8, 12, and 16 of histone H4; anti-acetyl H3 which recognizes N-terminally acetylated histone H3; and anti-IC3/94 monoclonal antisera which was used as a loading control and recognizes *P. falciparum* rhoptry associated protein 2 (RAP2) [40]. IRDye[®] secondary antibodies (LI-COR Biosciences) were used and membranes imaged using an Odyssey infrared imaging system (LI-COR biosciences).

4.7. Deacetylase assays

Recombinant *Pf*HDAC1 (Sigma-Aldrich, USA) and *P. falciparum* nuclear protein lysates were tested for deacetylase activity using a fluorometric HDAC Assay Kit (Merck Millipore, USA), as per the manufacturers' instructions. Preparation of *P. falciparum* nuclear lysates from trophozoite stage parasites was carried out using a NucBuster protein extraction kit (Calbiochem, USA), according to the manufactures instructions. *Pf*HDAC1 activity was assessed using Fluorogenic HDAC substrate 3 (BPS Bioscience, USA). Assays were carried out in duplicate, on two separate occasions and data presented as mean ($\pm$ SD) % inhibition compared to controls.

4.8. Late stage *P. falciparum* (IV–V) anti-gametocyte assay

Late stage gametocyte viability assays were carried out using highly synchronous stage IV gametocytes induced from transgenic NF54 *P. falciparum* parasites expressing the gametocyte specific protein, *Pfs*16, fused to green fluorescent protein (NF-54-pfs16-GFP), as described previously [41]. Gametocytes were harvested by magnetic isolation on day 8 post induction then added to 384 well imaging plates at 33,000 gametocytes per well. Following the addition of test or control compounds, cells were incubated for 72 h under reduced oxygen tension (5% CO₂, 5% O₂, 80% N₂). Mitotracker Red CM-H2XRos was then added to each well (0.07ug/ml) and the cells were incubated overnight as described above. DMSO (0.4%) and puromycin (5μM) were used as controls in each assay. Gametocyte viability was evaluated on an OPERA™ (PerkinElmer) High Content Screening System. Images acquired for GFP and Mitotracker Red CM-H2XRos were overlaid and the number of elongated viable gametocytes per image was determined using a script based on Acapella™ software, developed for use with the OPERA™ imaging system. Percent inhibition compared to DMSO vehicle controls was calculated and mean IC₅₀ values ($\pm$ SD) determined by non-linear regression analysis, sigmoidal dose response (variable slope) fit using Prism 4.0 for two separate experiments in duplicate point.

4.8.1. Principle of script used for image analysis—Maximal fluorescent pixel intensities are identified for the MTR acquired image and the average intensity for designated objects calculated. Objects with an average fluorescent MTR intensity, above an assay specified classification of minimal MTR signal, are identified as viable objects. GFP positive objects are identified and overlaid with the MTR positive objects. The GFP objects with a MTR positive signal are then evaluated for the characteristic of being at least four times longer than they are wide. Objects that are both MTR positive and GFP object elongated are identified as viable late stage gametocytes.

4.9. Pb liver stage assay

4.9.1 Parasites—*P. berghei* Luciferase sporozoites from MR4 (MRA-868) [42] were obtained by dissection of infected *Anopheles stephensi* mosquito salivary glands. Dissected salivary glands were homogenized in a glass tissue grinder and filtered twice through nylon cell strainers (40 μm pore size, BD Falcon 087711) and counted using a hemocytometer. The sporozoites were kept on ice until needed.

4.9.2 Cell lines—HepG2-A16-CD81EGFP cells stably transformed to express a GFP-CD81 fusion protein [43] were cultured at 37°C in 5% CO₂ in DMEM (Invitrogen, Carlsbad, USA) supplemented with 10% FCS, and 1× Penicillin-Streptomycin-Glutamine (Gibco, Life Technologies, USA).

4.9.3 Sporozoite infection—We used *P. berghei* for this screen since its higher infection rates of immortal human liver cell lines are more conducive to high throughput screening than the infection rates of human malaria parasites. *P. berghei* is able to infect human hepatocarcinoma HepG2 cells expressing the tetraspanin CD81 receptor [43,44]. 3×10³ HepG2-A16-CD81EGFP cells in 5 µl of medium (2×10⁵ cells/ml, 5% FBS, 5× Penicillin-Streptomycin-Glutamine (Gibco, Life Technologies, USA)) were seeded in 1536-well plates (Greiner BioOne white solid bottom, custom GNF mold) 20–26 hours prior to the actual infection. 18 hours prior to infection, 50 nl of compound in DMSO (0.5% final DMSO concentration per well) were transferred with a PinTool (GNF Systems) or Echo liquid handler (LabCyt) into the assay plates. Atovaquone (12-point serial dilution starting at 10 µM) and 0.5% DMSO were used as positive and negative controls, respectively. *P. berghei* Luciferase sporozoites were freshly dissected as described above and their concentration adjusted to 200 sporozoites per µl (final concentration: 1000 sporozoites per well) with 5× Penicillin-Streptomycin-Glutamine (Gibco, Life Technologies, USA) in DMEM (Invitrogen). The increased antibiotic concentration did not interfere with the parasite or HepG2-A16-CD81EGFP growth. The HepG2-A16-CD81EGFP cells were then infected with 1×10³ sporozoites per well (5 µl) with a single tip Bottle Valve liquid handler (GNF Systems), and the plates spun down at 37°C for 3 minutes in an Eppendorf 5810 R centrifuge with a centrifugal force of 330xg on lowest acceleration and brake setting. The plates were then incubated at 37°C for 48 hours in 5% CO₂ with high humidity to minimize media evaporation and edge effect. After incubation, media was removed by spinning the inverted plates at 150xg for 30 seconds. 2 µl BrightGlo luciferase (Promega) were dispensed with the MicroFlo (BioTek) liquid handler. Immediately after addition of the luminescence reagent, the plates were vortexed at median intensity setting for 10 seconds and read by an EnVision Multilabel Reader (PerkinElmer). IC₅₀ values were determined using a non-linear variable slope four parameter regression curve fitting model in Prism 6 (GraphPad Software Inc).

4.9.4 HepG2 toxicity assay—HepG2 viability after 56 hours was used to assess compound toxicity. Specifically we assayed ATP levels of live HepG2 host cells and compared them to ATP levels of DMSO-treated control cells. Hepatocytes were cultured as described above, but on the day of infection, instead of sporozoites, 5µl media was added with a MicroFlo (BioTek) liquid handler. After the 48 hours incubation period, media was removed by spinning the inverted plates at 150xg for 30 seconds. 2 µl of CellTiterGlo (Promega) diluted 1:1 with ddH₂O were dispensed with the MicroFlo (BioTek) liquid handler and read by an EnVision Multilabel Reader (PerkinElmer). IC₅₀ values were determined as described above (4.9.3)

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding Sources

This work was supported by the Australian Research Council (FT0991213 to KTA; LP120200557 to VMA), Medicines for Malaria Ventures (MMV) (to SM and VMA) as well as the Bill and Melinda Gates Foundation, MMV, and NIH (R01AI090141) (to EAW).

We thank the Australian Red Cross Blood Service for the provision of human blood and sera. The Deutsche Forschungsgemeinschaft (DFG) is acknowledged for funds used to purchase the UHR-TOF maXis 4G, Bruker Daltonics, Bremen HRMS instrument used in this research.

Abbreviations

DIC	<i>N,N'</i> -diisopropylcarbodiimide
DMF	<i>N,N</i> -dimethylformamide
EEF	exo-erythrocytic form
HDAC	histone deacetylase
<i>Pf</i>	<i>Plasmodium falciparum</i>
<i>Pf</i> LSG	<i>P. falciparum</i> NF54 late stage gametocytes (IV–V)
<i>Pb</i>	<i>Plasmodium berghei</i>
RT	room temperature
SAHA	suberoylanilide hydroxamic acid
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TSA	trichostatin A

References

1. World Health Organization. World Malaria Report 2011. WHO Press; Geneva: 2012.
2. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. Global malaria mortality between 1980 and 2010: a systematic analysis. *Lancet*. 2012; 379:413–431. [PubMed: 22305225]
3. Abdulla S, Salim N, Machera F, Kamata R, Juma O, Shomari M, Kubhoja S, Mohammed A, Mwangoka G, Aebi T, Mshinda H, Schellenberg D, Carter T, Villafana T, Dubois MC, Leach A, Lievens M, Vekemans J, Cohen J, Ballou WR, Tanner M. Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region. *Malar J*. 2013; 12:11. [PubMed: 23297680]
4. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspá M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, Mtoro A, Sykes A, Ahmed S, Urassa AM, Ali AM, Mwangoka G, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Tahita MC, Kabore W, Ouedraogo S, Sandrine Y, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Otero C, Onoko M, Otieno K, Awino N, Omoto J, Williamson J, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Nekoye O, Gondi S, Otieno A, Ogutu B, Wasuna R, Owira V, Jones D, Onyango AA, Njuguna P, Chilengi R, Akoo P, Kerubo C, Gitaka J, Maingi C, Lang T, Olotu A, Tsofa B, Bejon P, Peshu N, Marsh K, Owusu-Agyei S, Asante KP, Osei-Kwakye K,

Boahen O, Ayamba S, Kayan K, Owusu-Ofori R, Dosoo D, Asante I, Adjei G, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Kilavo H, Mahende C, Liheluka E, Lemnge M, Theander T, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, Sylverken J, Sambian D, Agyekum A, Owusu L, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Msika A, Jumbe A, Chome N, Nyakuipa D, Chintedza J, Ballou WR, Bruls M, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Vekemans J, Carter T, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. *N Engl J Med*. 2011; 365:1863–1875. [PubMed: 22007715]

5. Turschner S, Efferth T. Drug resistance in *Plasmodium*: natural products in the fight against malaria. *Mini Rev Med Chem*. 2009; 9:206–214. [PubMed: 19200025]
6. Dondorp AM, Nosten F, Yi P, Das D, Phyto AP, Tarning J, Lwin KM, Arie F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. 2009; 361:455–467. [PubMed: 19641202]
7. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, von Seidlein L. Artemisinin resistance: current status and scenarios for containment. *Nat Rev Microbiol*. 2010; 8:272–280. [PubMed: 20208550]
8. The maIERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. *PLoS Med*. 2011; 8:e1000402. [PubMed: 21311580]
9. Burrows JN. Antimalarial drug discovery: where next? *Future Med Chem*. 2012; 4:2233–2235. [PubMed: 23234546]
10. Rodrigues T, Prudêncio M, Moreira R, Mota MM, Lopes F. Targeting the liver stage of malaria parasites: a yet unmet goal. *J Med Chem*. 2012; 55:995–1012. [PubMed: 22122518]
11. Dechy-Cabaret O, Benoit-Vical F. Effects of antimalarial molecules on the gametocyte stage of *Plasmodium falciparum*: the debate. *J Med Chem*. 2012; 55:10328–10344. [PubMed: 23075290]
12. Lucantoni L, Avery V. Whole-cell in vitro screening for gametocytocidal compounds. *Future Med Chem*. 2012; 4:2337–2360. [PubMed: 23234555]
13. Andrews KT, Tran TN, Fairlie DP. Towards histone deacetylase inhibitors as new antimalarial drugs. *Curr Pharm Des*. 2012; 18:3467–3479. [PubMed: 22607140]
14. Andrews KT, Tran TN, Wheatley NC, Fairlie DP. Targeting histone deacetylase inhibitors for anti-malarial therapy. *Curr Top Med Chem*. 2009; 9:292–308. [PubMed: 19355992]
15. Biel M, Wascholowski V, Giannis A. Epigenetics – an epicenter of gene regulation: histones and histone-modifying enzymes. *Angew Chem Int Ed*. 2005; 44:3186–3216.
16. Bertrand P. Inside HDAC with HDAC inhibitors. *Eur J Med Chem*. 2010; 45:2095–2116. [PubMed: 20223566]
17. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? *Cancer Lett*. 2009; 277:8–21. [PubMed: 18824292]
18. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. *Oncogene*. 2007; 26:5541–5552. [PubMed: 17694093]
19. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. *Oncogene*. 2007; 26:5310–5318. [PubMed: 17694074]
20. Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step? *Cancer Lett*. 2009; 280:211–221. [PubMed: 19289255]
21. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. *Immunol Cell Biol*. 2012; 90:85–94. [PubMed: 22124371]
22. Horrocks P, Wong E, Russell K, Emes RD. Control of gene expression in *Plasmodium falciparum* - Ten years on. *Mol Biochem Parasit*. 2009; 164:9–25.
23. Patel V, Mazitschek R, Coleman B, Nguyen C, Uргаonkar S, Cortese J, Barker RH, Greenberg E, Tang W, Bradner JE, Schreiber SL, Duraisingh MT, Wirth DF, Clardy J. Identification and characterization of small molecule inhibitors of a class I histone deacetylase from *Plasmodium falciparum*. *J Med Chem*. 2009; 52:2185–2187. [PubMed: 19317450]
24. Hu G, Cabrera A, Kono M, Mok S, Chaal BK, Haase S, Engelberg K, Cheemadan S, Spielmann T, Preiser PR, Gilberger TW, Bozdech Z. Transcriptional profiling of growth perturbations of the

- human malaria parasite *Plasmodium falciparum*. Nat Biotechnol. 2010; 28:91–98. [PubMed: 20037583]
25. Andrews KT, Gupta AP, Tran TN, Fairlie DP, Gobert GN. Comparative gene expression profiling of *P. falciparum* malaria parasites exposed to three different histone deacetylase inhibitors. PLoS ONE. 2012; 7:e31847. [PubMed: 22384084]
26. Chaal BK, Gupta AP, Wastuwidyaningtyas BD, Luah YH, Bozdech Z. Histone deacetylases play a major role in the transcriptional Regulation of the *Plasmodium falciparum* life cycle. PLoS pathogens. 2010; 6:e1000737. [PubMed: 20107518]
27. Mok S, Imwong M, Mackinnon MJ, Sim J, Ramadoss R, Yi P, Mayxay M, Chotivanich K, Liong KY, Russell B, Socheat D, Newton PN, Day NPJ, White NJ, Preiser PR, Nosten F, Dondorp AM, Bozdech Z. Artemisinin resistance in *Plasmodium falciparum* is associated with an altered temporal pattern of transcription. BMC genomics. 2011; 12:391. [PubMed: 21810278]
28. Dow GS, Chen Y, Andrews KT, Caridha D, Gerena L, Gettayacamin M, Johnson J, Li Q, Melendez V, Obaldia N, Tran TN, Kozikowski AP. Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. Antimicrob Agents Chemother. 2008; 52:3467–3477. [PubMed: 18644969]
29. Sumanadasa SDM, Goodman CD, Lucke AJ, Skinner-Adams T, Sahama I, Haque A, Do TA, McFadden GI, Fairlie DP, Andrews KT. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob Agents Chemother. 2012; 56:3849–3856. [PubMed: 22508312]
30. Marek L, Hamacher A, Hansen FK, Kuna K, Gohlke H, Kassack MU, Kurz T. Histone Deacetylase (HDAC) Inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 2013; 56:427–436. [PubMed: 23252603]
31. Duléry V, Renaudet O, Dumy P. Ethoxyethylidene protecting group prevents Noveracylation in aminooxy peptide synthesis. Tetrahedron. 2007; 63:11952–11958.
32. Foillard S, Rasmussen MO, Razkin J, Boturn D, Dumy P. 1-Ethoxyethylidene, a new group for the stepwise SPPS of aminooxyacetic acid containing peptides. J Org Chem. 2008; 73:983–991. [PubMed: 18173281]
33. Draghici B, Hansen FK, Buciumas AM, El-Gendy BEDM, Todadze E, Katritzky AR. Efficient microwave-assisted synthesis of aminoxy acid conjugates. RSC Adv. 2011; 1:602–606.
34. Jiménez-Castells C, de la Torre BG, Gutiérrez Gallego R, Andreu D. Optimized synthesis of aminooxy-peptides as glycoprobe precursors for surface-based sugar-protein interaction studies. Bioorg Med Chem Lett. 2007; 17:5155–5158. [PubMed: 17629701]
35. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46:3–26. [PubMed: 11259830]
36. Hansen FK, Skinner-Adams TS, Duffy S, Marek L, Sumanadasa SDM, Kuna K, Held J, Avery VM, Andrews KT, Kurz T. Synthesis, antimalarial properties and SAR studies of alkoxyurea-based HDAC inhibitors. ChemMedChem. 2014 in press.
37. Jones B. The halogenation of phenolic ethers and anilides. Part XIV. *m*-Substituted phenyl ethers. J Chem Soc. 1943:430–432.
38. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979; 16:710–718. [PubMed: 394674]
39. Huber W, Koella JC. A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop. 1993; 55:257–261. [PubMed: 8147282]
40. Baldi DL, Andrews KT, Waller RF, Roos DS, Howard RF, Crabb BS, Cowman AF. RAP1 controls rhoptry targeting of RAP2 in the malaria parasite *Plasmodium falciparum*. EMBO J. 2000; 19:2435–2443. [PubMed: 10835342]
41. Duffy S, Avery VM. Identification of inhibitors of *Plasmodium falciparum* gametocyte development. Malar J. 2013; 12:408. [PubMed: 24206914]
42. Janse CJ, Franke-Fayard B, Mair GR, Ramesar J, Thiel C, Engelmann S, Matuschewski K, van Gemert GJ, Sauerwein RW, Waters AP. High efficiency transfection of *Plasmodium berghei*

- facilitates novel selection procedures. *Mol Biochem Parasitol*. 2006; 145:60–70. [PubMed: 16242190]
43. Yalaoui S, Zougbedé S, Charrin S, Silvie O, Arduise C, Farhati K, Boucheix C, Mazier D, Rubinstein E, Froissard P. Hepatocyte permissiveness to *Plasmodium* infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain. *PLoS Pathog*. 2008; 4:e1000010. [PubMed: 18389082]
44. Silvie O, Rubinstein E, Franetich JF, Prenant M, Belnoue E, Rénia L, Hannoun L, Eling W, Levy S, Boucheix C, Mazier D. Hepatocyte CD81 is required for *Plasmodium falciparum* and *Plasmodium yoelii* sporozoite infectivity. *Nat Med*. 2003; 9:93–96. [PubMed: 12483205]

Highlights

- 13 novel HDACIs have been synthesized using a straightforward solid-phase protocol
- Several HDACIs showed potent activity against three malaria life cycle stages
- The nature of the cap group is crucial for the parasite selectivity
- HDACIs represent a valuable starting point for the development of new antimalarials

Figure 1. Hyperacetylation of *P. falciparum* histones

Trophozoite-stage *P. falciparum* 3D7 parasites were treated for 3h with 500 nM chloroquine (CQ), TSA, or compounds **1a–1d** or **1i–1l**. Parasites treated with vehicle only (0.05% DMSO) served as negative controls and were taken at the start of the treatment (C-0) and after 3h (C-3). Protein lysates were analysed by Western blot with antisera that recognize tetra-acetylated histone H4 (**anti-acetyl H4**) or N-terminally acetylated histone H3 (**anti-acetyl H3**). In each case the same membranes were also probed with antisera that recognizes *P. falciparum* RAP2 (anti-IC3/94) to show equivalent loading between lanes.

Scheme 1.

Solid-phase synthesis of alkoxyamide-based HDAC inhibitors **1i-u**.^a

^aReagents and conditions: a) (i) piperidine, DMF, RT, 1 h; (ii) 6-((1,3-dioxoisindolin-2-yl)oxy)hexanoic acid, DIC, Oxyma, CH₂Cl₂, RT, 24 h; b) methylhydrazine, ethanol, THF, RT, 3 h; c) RCOOH, DIC, Oxyma, CH₂Cl₂, RT, 24 h; d) TFA, CH₂Cl₂, RT, 1 h.

Table 1

Structures and properties of selected hydroxamate-based HDAC inhibitors.

Name	Structure	MW	<i>P. falciparum</i> IC ₅₀ [μM]	Mammalian cell cytotoxicity IC ₅₀ [μM]	SI ^a
Vorinostat (SAHA) ^b		264	0.109 – 0.309	2.200 – >20	7 – >183
Trichostatin A (TSA) ^b		302	0.008 – 0.011	0.200	18 – 25
2-ASA-9 ^b		461	0.015 – 0.039	1.240	32 – 82
WR301801 (YC-II-88) ^c		362	0.0006 – 0.0018	0.600	333–1000
SB939 ^d		358	0.080 – 0.150	0.800 – >100	4 – >1250

^a Selectivity index, mammalian cell IC₅₀/IC₅₀ *P. falciparum*.^b data from reference 25.^c data from reference 28.

data from reference 29.
 p

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2

Calculated logP values, *in vitro* activity against asexual blood stages of *P. falciparum* 3D7 parasites, cytotoxicity and selectivity indices of **1a** – **1u**.

Compound	R	logP ^a	<i>Pf</i> 3D7 ^b IC ₅₀ [μM]	HepG2 IC ₅₀	95% CI for HepG2 IC ₅₀ [μM]	SI ^c
1a	3,5-CH ₃ -Ph	2.05 (±0.57)	0.10 (±0.02)	1.26	1.06 – 1.51	13
1b	3,4-CH ₃ -Ph	2.05 (±0.57)	0.12 (±0.03)	3.24	2.50 – 4.19	27
1c	4- <i>i</i> -Pr-Ph	2.47 (±0.57)	0.12 (±0.02)	8.76	5.68 – 13.51	73
1d	3-CH ₃ -Ph	1.59 (±0.56)	0.19 (±0.06)	4.69	3.83 – 5.73	25
1e	4-CH ₃ -Ph	1.59 (±0.56)	0.22 (±0.02)	12.11	8.49 – 17.28	55
1f	4-CF ₃ -Ph	2.10 (±0.58)	0.26 (±0.03)	12.96	10.33 – 16.27	50
1g	4-F-Ph	1.35 (±0.59)	0.58 (±0.14)	10.33	8.33 – 12.81	18
1h	2-CH ₃ -Ph	1.59 (±0.56)	1.12 (±0.19)	12.74	10.19 – 15.94	11
1i	4- <i>t</i> -Bu-Ph	2.82 (±0.57)	0.09 (±0.03)	12.47	7.24 – 21.47	139
1j	4- <i>i</i> -PrO-Ph	2.17 (±0.57)	0.15 (±0.03)	9.76	7.00 – 13.61	65
1k	4-Ph'-Ph	2.77 (±0.58)	0.16 (±0.03)	10.24	8.66 – 12.10	64
1l	4-BuO-Ph	2.89 (±0.57)	0.17 (±0.03)	>50		>294
1m	4-PrO-Ph	2.36 (±0.57)	0.21 (±0.02)	16.86	10.92 – 26.06	80
1n	4-C ₅ H ₁₁ O-Ph	3.42 (±0.57)	0.21 (±0.04)	>50		>238
1o	4-C ₂ H ₅ O-Ph	1.82 (±0.57)	0.23 (±0.05)	7.68	4.68 – 12.61	33
1p	2-PrO-Ph	1.92 (±0.57)	0.24 (±0.02)	8.12	4.64 – 14.23	34
1q	3-PrO-Ph	2.36 (±0.57)	0.24 (±0.04)	7.04	4.27 – 11.59	29
1r	4-Bu-Ph	3.18 (±0.56)	0.26 (±0.08)	10.77	7.71 – 15.03	41
1s	4-C ₆ H ₁₃ O-Ph	3.95 (±0.57)	0.35 (±0.05)	>50		>143
1t	furan-2-yl	-0.08 (±0.58)	0.62 (±0.16)	8.03	6.04 – 10.69	13
1u	2-F-Ph	0.76 (±0.59)	0.73 (±0.05)	9.10	6.96 – 11.89	12
SAHA		0.86 (±0.21)	0.13 (±0.02) ^d	1.49	0.97 – 2.29	11
Chloroquine		4.69 (±0.32)	0.01 (±0.006)	>10		>1000

^a logP values were calculated using ACD/ChemSketch freeware version 12.01.

^b Three independent assays, each carried out in triplicate wells.

$SI = \frac{(mammalian\ cell\ IC_{50}) / (P. falciparum\ IC_{50}) - larger\ values\ indicate\ greater\ malaria\ parasite\ selectivity.}{c}$

d Data from reference 36. CI, confidence interval.

Table 3Inhibition of *P. falciparum* nuclear lysates and recombinant *Pf*HDAC1.

Compound	R	<i>Pf</i> nuclear lysate % inhibition at 1 μ M ^a	<i>Pf</i> HDAC1 % inhibition at 1 μ M ^a
1a	3,5-CH ₃ -Ph	58.6 ($\pm$ 12.5)	73.8 ($\pm$ 7.5)
1b	3,4-CH ₃ -Ph	93.3 ($\pm$ 2.4)	82.6 ($\pm$ 4.2)
1c	4- <i>i</i> -Pr-Ph	72.9 ($\pm$ 10.4)	67.2 ($\pm$ 0.5)
1d	3-CH ₃ -Ph	73.9 ($\pm$ 16.3)	75.5 (17.8)
1i	4- <i>t</i> -Bu-Ph	48.3 ($\pm$ 7.3)	68.6 ($\pm$ 1.2)
1j	4- <i>i</i> -PrO-Ph	9.3 ($\pm$ 4.6)	62.4 ($\pm$ 10.1)
1k	4-Ph'-Ph	89.3 ($\pm$ 0.2)	64.2 ($\pm$ 19.4)
1l	4-BuO-Ph	50.3 ($\pm$ 11.5)	72.1 ($\pm$ 5.0)
TSA		78.1 ($\pm$ 12.6)	93.3 ($\pm$ 10.9)

^a Average ($\pm$ SD) of two independent assays, each carried out in duplicate wells.

Table 4
Activity of alkoxyamide-based HDAC inhibitors against *P. berghei* exo-erythrocytic stages.

Compound	R	<i>Pb</i> EEF ^a IC ₅₀ [μM]	95% CI for <i>Pb</i> EEF IC ₅₀	HepG2 IC ₅₀	95% CI for HepG2 IC ₅₀	EEF SI ^b
1a	3,5-CH ₃ -Ph	0.16	0.12 – 0.21	1.26	1.06 – 1.51	8
1b	3,4-CH ₃ -Ph	0.31	0.23 – 0.42	3.24	2.50 – 4.19	10
1c	4- <i>i</i> -Pr-Ph	1.34	0.68 – 2.62	8.76	5.68 – 13.51	7
1d	3-CH ₃ -Ph	0.66	0.50 – 0.87	4.69	3.83 – 5.73	7
1e	4-CH ₃ -Ph	1.14	0.78 – 1.69	12.11	8.49 – 17.28	11
1f	4-CF ₃ -Ph	1.90	1.22 – 2.96	12.96	10.33 – 16.27	7
1g	4-F-Ph	2.31	1.46 – 3.64	10.33	8.33 – 12.81	4
1h	2-CH ₃ -Ph	2.54	1.68 – 3.86	12.74	10.19 – 15.94	5
1i	4- <i>i</i> -Bu-Ph	1.87	1.65 – 2.12	12.47	7.24 – 21.47	7
1j	4- <i>i</i> -PrO-Ph	1.36	0.86 – 2.13	9.76	7.00 – 13.61	7
1k	4-Ph-Ph	1.83	1.51 – 2.22	10.24	8.66 – 12.10	6
1l	4-BuO-Ph	2.14	1.14 – 4.01	>50		>23
1m	4-PrO-Ph	~5.29	(Very wide)	16.86	10.92 – 26.06	~3
1n	4-C ₅ H ₁₁ O-Ph	~5.14	(Very wide)	>50		>10
1o	4-C ₂ H ₅ O-Ph	1.37	0.86 – 2.18	7.68	4.68 – 12.61	6
1p	2-PrO-Ph	0.48	0.32 – 0.72	8.12	4.64 – 14.23	17
1q	3-PrO-Ph	0.45	0.30 – 0.68	7.04	4.27 – 11.59	16
1r	4-Bu-Ph	~1.79	(Very wide)	10.77	7.71 – 15.03	~6
1s	4-C ₆ H ₁₃ O-Ph	7.91	4.60 – 13.62	>50		>6
1t	furan-2-yl	1.13	0.72 – 1.78	8.03	6.04 – 10.69	7
1u	2-F-Ph	1.25	0.68 – 2.28	9.10	6.96 – 11.89	7
SAHA		0.14	0.11 – 0.20	1.49	0.97 – 2.29	11
Chloroquine		>10		>10		-
Atovaquone		0.00016	0.000085 – 0.00028	>10		>64102

^a *P. berghei* exo-erythrocytic forms (EEF).

^b SI = (mammalian cell IC₅₀)/(*Pb* EEF IC₅₀) – larger values indicate greater malaria parasite selectivity. CI, confidence interval.

Table 5Activity of alkoxyamide-based HDAC inhibitors against stage IV–V *P. falciparum* gametocytes.

Compound	R	<i>Pf</i> LSG ^a IC ₅₀ [μM]
1a	3,5-CH ₃ -Ph	0.33 ^b (±0.01)
1b	3,4-CH ₃ -Ph	0.25 ^b (±0.10)
1d	3-CH ₃ -Ph	0.43 ^b (±0.1)
1g	4-F-Ph	2.0 ^b (±0.01)
1i	4- <i>t</i> -Bu-Ph	>120 ^{cd}
1k	4-Ph'-Ph	0.50 ^b (±0.14)
1r	4-Bu-Ph	5.3 ^c
1t	furan-2-yl	1.0 ^b (±0.2)
1u	2-F-Ph	>120 ^{cd}
Artesunate		0.0038 (±0.0003) ^b
Pyronaridine		2.7 (±0.87) ^e
Chloroquine		>120 ^b

^a *P. falciparum* NF54 late stage gametocytes (IV–V).^b n=2, each in duplicate wells.^c n=1, each in duplicate wells.^d No activity at 120 μM.^e n=7, each in duplicate wells. *nd*, not determined.